3S Pharmaceutical Group
3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.
3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.
We look forward to having opportunity to discuss potential collaboration with you.
Zhao Peng
Senior BD ManagerAeola Health Solutions
the world of healthcare one sector at a time.
We consolidate CROs and medical labs.
Mr. Michael Ezem
Aeola Health SolutionsAnsun Biopharma
Max Wang
BDBiomissile Biotech
苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台,其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体,酵母菌,和哺乳动物细胞展示平台。公司依托平台优势,在较短的时间内已经拥有十多个在研全新生物大分子药物,包括多个国际上首创的全人源纳米抗体(VH)和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。
Chao Tu
President & CEOBioPegasus, LLC
BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.
BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.
BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.
Dr. Tianlin Ma
FounderBiosion Inc.,
During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.